当前位置: 首页 > 期刊 > 《中国医学创新》 > 2021年第36期
编号:185103
结直肠癌免疫疗法的研究进展
http://www.100md.com 2021年3月24日 中国医学创新 2021年第36期
     靳增彩 郝淑兰 刘丽坤

    【摘要】 结直肠癌是世界上第三大常见癌症,发病率和死亡率在全球范围内不断增加。结直肠癌的标准治疗一直是手术、放射治疗和化学疗法。然而,这些治疗具有非特异性,对正常细胞具有细胞毒性。此外,许多患者经一系列治疗后仍会复发。因此,治疗结直肠癌更有效的替代疗法的出现至关重要。免疫疗法是癌症治疗的新选择之一,该策略利用患者自身的免疫系统对抗癌细胞。免疫疗法具有特异性,正常细胞不受影响。在某些情况下,免疫疗法的结果令人惊讶,但有些依赖于患者自身免疫系统状态的效果不佳。对免疫疗法反应好的患者具有更好的预后和生活质量。

    【关键词】 结直肠癌 免疫疗法 T细胞 抗体 细胞因子

    Advances in Immunotherapy of Colorectal Cancer/JIN Zengcai, HAO Shulan, LIU Likun. //Medical Innovation of China, 2021, 18(36): -179

    [Abstract] Colorectal cancer is the third most common cancer in the world, and the incidence rate and mortality rate increase worldwide. The standard treatment for colorectal cancer has been surgery, radiotherapy and chemotherapy. However, these treatments are nonspecific and cytotoxic to normal cells. In addition, many patients will relapse after a series of treatment. Therefore, the emergence of more effective alternative therapies for colorectal cancer is crucial. Immunotherapy is one of the new options for cancer treatment, the strategy uses the patient’s own immune system to fight against cancer cells. Immunotherapy is specific and normal cells are not affected. In some cases ......

您现在查看是摘要页,全文长 21247 字符